Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management


Background: Epilepsy is commonly associated with reproductive endocrine disorders. These include polycystic ovary syndrome (PCOS), isolated components of this syndrome such as polycystic ovaries, hyperandrogenaemia, hypothalamic amenorrhoea, and functional hyperprolactinaemia.

Objective: To summarise the currently known relations between epilepsy and reproductive endocrine disorders.

Methods: A review of clinical experience and published reports.

Results: The most likely explanations for endocrine disorders related to epilepsy or antiepileptic drugs are: (1) a direct influence of the epileptogenic lesion, epilepsy, or antiepileptic drugs on the endocrine control centres in the brain; (2) the effects of antiepileptic drugs on peripheral endocrine glands; (3) the effects of antiepileptic drugs on the metabolism of hormones and binding proteins; and (4) secondary endocrine complications of antiepileptic drug related weight changes or changes of insulin sensitivity. Regular monitoring of reproductive function at visits is recommended, including questioning about menstrual disorders, fertility, weight, hirsutism, and galactorrhoea. Particular attention should be paid to patients on valproate and obese patients or those experiencing significant weight gain. Single abnormal laboratory or imaging findings without symptoms may not constitute a clinically relevant endocrine disorder. However, patients with these kinds of abnormalities should be monitored to detect the possible development of a symptomatic disorder associated with, for example, menstrual disorders or fertility problems.

Conclusions: If a reproductive endocrine disorder is found, antiepileptic drug treatment should be reviewed to ensure that it is correct for the particular seizure type and that it is not contributing to the endocrine problem. The possible benefits of a change in treatment must be balanced against seizure control and the cumulative side effect of alternative agents.

The first aim in the treatment of patients with epilepsy is the suppression of seizures. Epilepsy can, however, also be associated with other pathological changes which may require investigation and treatment. Such changes include endocrine disorders, and in particular those affecting the reproductive system in women. Reproductive endocrine disorders described in this context include polycystic ovary syndrome, hypothalamic amenorrhoea, premature ovarian failure, and functional hyperprolactinaemia. The recognition of reproductive endocrine disorders in women with epilepsy is important because they may have serious long term consequences and may be treatable. These disorders contribute to the unusually high rate of infertility among women with epilepsy. Reproductive endocrine disorders, such as polycystic ovary syndrome (PCOS), may also be associated with higher rates of migraine, emotional disorders, and female malignancies. It has been suggested, moreover, that anovulatory cycles, which are characteristic of reproductive endocrine disorders, may be associated with higher seizure frequencies.

We summarise some of the currently known relations between epilepsy and reproductive endocrine disorders to enable physicians involved in the treatment of women with epilepsy to develop evidence based principles for the investigation and management of endocrine problems.

EVALUATION OF WOMEN WITH EPILEPSY FOR REPRODUCTIVE ENDOCRINE DISORDERS

The frequent occurrence of reproductive endocrine disorders in women with epilepsy makes it important for the neurologist to recognise characteristic symptoms and signs. The evaluation of reproductive endocrine disorders typically falls into the domain of the endocrinologist and gynaecologist. The investigation of endocrine problems in patients with epilepsy, however, may well require close cooperation between neurologists and endocrinologists or gynaecologists, as these specialists may not have a detailed understanding of the effects of epilepsy or antiepileptic drugs on the endocrine system.

In table 1 we summarise some of the common clinical features of reproductive endocrine disorders. These include menstrual irregularity, infertility, weight gain, hirsutism, and galactorrhoea. In table 2 we list some of the investigations that are commonly carried out to diagnose reproductive endocrine disorders. Tests include hormonal measurements, pelvic ultrasonography, and pituitary imaging. We also list the implications of the findings.

Pelvic ultrasonography is indicated if clinical features or hormonal tests raise concern about ovarian pathology. Transvaginal ultrasound is more sensitive than transabdominal ultrasound in the identification of structural abnormalities of the ovaries, including tumours and cystic change. Pituitary magnetic resonance imaging may be indicated if the clinical features (for example, galactorrhoea) or the laboratory results (such as hyperprolactinaemia) suggest an abnormality of the hypothalamic-pituitary axis. However, a small pituitary lactotroph adenoma may not be detected if beyond the resolution of magnetic resonance imaging.

www.jnnp.com
PCOS is a common cause of irregular periods in women. It is considered to affect approximately 4–6% of women in the general population. The prevalence of PCOS in patients with temporal lobe epilepsy has been found to be between 10% and 25% even if they were not receiving antiepileptic drugs.

PCOS is a form of hyperandrogenic chronic anovulation. Anovulation may be indicated by low mid-luteal phase progesterone levels. The pathogenesis of PCOS involves the acceleration of pulsatile gonadotropin releasing hormone (GnRH) secretion, insulin resistance, hyperinsulinaemia, and downstream metabolic dysregulation. Abnormalities of the reproductive axis are manifested as hypersecretion of luteinising hormone, ovarian theca stromal cell hyperactivity, and hypofunction of the follicle stimulating hormone (FSH)–granulosa cell axis resulting in hyperandrogenism, hirsutism, and ovarian theca stromal cell hyperactivity, and reproductive axis are manifested as hypersecretion of luteinising hormone; PCOS, polycystic ovary syndrome.

DHEAS Measurement of serum level Age 20–29 >3800 ng/ml Rule out non-classical adrenal hyperplasia

LH, FSH Measurement of serum levels
FSH >35 IU/l, LH >11 IU/l Suggestive of PCOS
FSH <7 IU/ml Rule out adrenal/ovarian tumour

DHEAS Measurement of serum level Age 30–39 >2700 ng/ml Suggestive of obesity

Pelvic ultrasound Transvaginal or transabdominal (day 3 to 9 of the cycle)
>10 peripheral cysts, 2–8 mm diameter in one ultrasound plane, thickening of ovarian stroma
Other structural abnormalities of ovaries

Glucose/insulin Fasting, morning levels; glucose/insulin ratio
Fasting glucose >7.8 mmol/l Suggestive of diabetes
Glucose/insulin ratio >4 Suggestive of reduced insulin sensitivity; associated with obesity and PCOS

Androstenedione Measurement of serum level >4.0 nmol/l Rule out adrenal/ovarian tumour
>10.0 nmol/l Rule out non-classical congenital adrenal hyperplasia

Progesterone Measurement of serum level (blood taken during mid-luteal phase according to menstrual cycle)
<6 nmol/l Low levels indicate anovulation; common cause: PCOS, HA, HPRL
>20 µg/l May be mildly raised in patients with epilepsy; rule out hypothryoidism or pituitary tumour; drugs may have impact on PRL levels

Testosterone Measurement of serum level (day 3–6 of the cycle)
<2.5 nmol/l Common cause: PCOS, valproate; non-classical adrenal hyperplasia may cause modest elevation of testosterone
>20 µg/l Common cause: PCOS, HA, HPRL

Prolactin Measurement of morning resting serum levels (not postictal!)
LH <7 IU/ml Suggestive of hypothalamic amenorrhoea
FSH >35 IU/l, LH >11 IU/l Suggestive of PCOS

BMI, body mass index; PCOS, polycystic ovary syndrome; WHR, waist/hip ratio.

Table 1 Clinical features of reproductive endocrine disorders in women with epilepsy

<table>
<thead>
<tr>
<th>Symptom/sign</th>
<th>Method</th>
<th>Abnormal findings</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Menstrual irregularity</td>
<td>Menstrual chart for at least 6 months</td>
<td>• ≥23 days: polymenorrhoea</td>
<td>Look for other symptoms of endocrine disorder including thyroid dysfunction; investigate or refer for investigation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• ≥35 days: oligomenorrhoea</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• No bleeding ≥6 months: amenorrhoea</td>
<td></td>
</tr>
<tr>
<td>Infertility</td>
<td>Clinical history</td>
<td>Inability to conceive after more than 12 months of regular unprotected intercourse and exclusion of male causes</td>
<td>Assess menstrual regularity. Endocrinologist and/or gynaecologist should be consulted to exclude endocrine disorders such as PCOS, hypothalamic amenorrhoea, hyperprolactinaemia, thyroid dysfunction</td>
</tr>
<tr>
<td>Obesity and weight gain</td>
<td>BMI (weight)/(kg)/height² (cm)</td>
<td>• Obese: BMI ≥25</td>
<td>Assess menstrual regularity. In case of cycle disturbance: investigate or refer</td>
</tr>
<tr>
<td></td>
<td>WHR: ratio of supine circumference of waist/hips</td>
<td>• Significant weight gain: ≥5 kg</td>
<td></td>
</tr>
<tr>
<td>Hirsutism</td>
<td>Inspection or Ferriman-Gallwey score History</td>
<td>Truncal obesity: WHR &gt;0.9</td>
<td>Assess menstrual regularity. In case of cycle disturbance: investigate or refer</td>
</tr>
<tr>
<td>Galactorrhoea</td>
<td></td>
<td>Male escutcheon</td>
<td>May be genetic or ethnic. Assess menstrual regularity. In case of cycle disturbance: investigate or refer</td>
</tr>
</tbody>
</table>

Table 2 Investigation of women with epilepsy and symptoms or signs of reproductive endocrine disorder

<table>
<thead>
<tr>
<th>Test</th>
<th>Method</th>
<th>Abnormal findings</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>LH, FSH</td>
<td>Measurement of serum levels (calculation based on an average of three estimations taken 20 minutes apart between day 3 and 6 of the cycle)</td>
<td>LH/FSH ratio &gt;2</td>
<td>Suggestive of PCOS</td>
</tr>
<tr>
<td>Progesterone</td>
<td>Measurement of serum level (blood taken during mid-luteal phase according to menstrual cycle)</td>
<td>&lt;6 nmol/l Low levels indicate anovulation; common cause: PCOS, HA, HPRL</td>
<td></td>
</tr>
<tr>
<td>Testosterone</td>
<td>Measurement of serum level day 3–6 of the cycle</td>
<td>&gt;2.5 nmol/l Common cause: PCOS, valproate; non-classical adrenal hyperplasia may cause modest elevation of testosterone</td>
<td>Rule out adrenal/ovarian tumour</td>
</tr>
<tr>
<td>Androstenedione</td>
<td>Measurement of serum level</td>
<td>&gt;4.0 nmol/l Rule out adrenal/ovarian tumour</td>
<td>Rule out non-classical congenital adrenal hyperplasia</td>
</tr>
<tr>
<td>DHEAS</td>
<td>Measurement of serum level Age 20–29 &gt;3800 ng/ml Age 30–39 &gt;2700 ng/ml</td>
<td>Suggestive of PCOS, obesity</td>
<td>Rule out non-classical adrenal hyperplasia</td>
</tr>
<tr>
<td>Glucose/insulin</td>
<td>Fasting, morning levels; glucose/insulin ratio</td>
<td>Fasting glucose &gt;7.8 mmol/l Suggestive of diabetes</td>
<td>Rule out non-classical adrenal hyperplasia</td>
</tr>
<tr>
<td>Pelvic ultrasound</td>
<td>Transvaginal or transabdominal (day 3 to 9 of the cycle)</td>
<td>&gt;10 peripheral cysts, 2–8 mm diameter in one ultrasound plane, thickening of ovarian stroma Other structural abnormalities of ovaries</td>
<td>Differentiating factors</td>
</tr>
</tbody>
</table>

PCOS should not be confused with isolated polycystic ovaries (polycystic change without its symptoms, pathological signs, or hormonal abnormality). Isolated polycystic ovaries are observed in 17–22% of women in the general population, although higher frequencies have been reported. In a population based study, polycystic ovaries was detected in 33% of women investigated (74/224). Two third of these women had menstrual irregularity and four fifths had at least one feature of PCOS, including menstrual irregularity, acne, hirsutism, obesity, and raised testosterone or luteinising hormone. The large number of women with PCOS in that study might result from a low recruitment rate (22% of all women approached) introducing a bias towards women with reproductive endocrine disorders.

The polycystic ovary structure is believed to develop in puberty in women because of a genetic predisposition. Only some women with polycystic ovaries will develop PCOS with chronic oligomenorrhea or amenorrhoea associated with increased serum androgen levels. There are many potential growth factors that affect polycystic ovaries and their development.
triggers for the development of PCOS, and weight gain is one such factor. Hypothalamic amenorrhoea, also called hypogonadotropic hypogonadism, has been found in 12% of 50 consecutive women with temporal lobe epilepsy whereas it is estimated to affect only 1.5% of the general population. Hypothalamic amenorrhoea is associated with a disturbed secretion of pituitary gonadotropins with low luteinising hormone levels. Hypothalamic amenorrhoea causes amenorrhoea or oligomenorrhea and infertility in the absence of signs of hyperandrogenaemia.

The menopause may occur earlier in women with epilepsy than in the general female population. In a series of 50 consecutive women with temporal lobectomy, Herzog et al. found that two women (4%) had primary gonadal failure with amenorrhoea and FSH values above 50 mIU/ml in their third decade of life, as compared with an expected occurrence of about 1% in the general population. In a recent study, perimenopause or menopause before 40 years of age was demonstrated in seven of 50 women (14%) with epilepsy, compared with three of 82 (4%) in a similarly aged normal control group (p < 0.05).

Interpretation of reproductive disorders in women with epilepsy

The most likely explanations for endocrine disorders related to epilepsy or antiepileptic drugs are as follows:

- a direct influence of the epileptogenic lesion, epilepsy, or antiepileptic drugs on the endocrine control centres in the brain (the hypothalamic-pituitary axis);
- the effects of antiepileptic drugs on peripheral endocrine glands;
- the effects of antiepileptic drugs on the metabolism of hormones and binding proteins;
- secondary endocrine complications of antiepileptic drug related weight changes or changes of insulin sensitivity.

A direct role for epilepsy in the pathogenesis of reproductive endocrine disorders is suggested by acute changes in serum prolactin and gonadotropin levels following seizures, a possible relation between the laterality of temporal lobectomy and the specific type of reproductive endocrine disorder (for example, left unilateral temporolimbic epilepsy has been associated with PCOS, right temporolimbic epilepsy with hypothalamic amenorrhoea), and the normalisation of menstrual cycles after epilepsy surgery.

Antiepileptic drugs have direct effects on peripheral female endocrine glands in animal models. Valproate has been shown to alter steroidogenesis and increase testosterone to oestradiol ratios in porcine ovarian follicles. Long term use of valproate increased the number of follicular cysts and altered sex steroid hormone levels in rats. Valproate, but not lamotrigine, increased the number of ovarian follicular cysts in rats. All of this experimental work was undertaken in non-epileptic animals. It remains to be proven that direct gonadal antiepileptic drug effects are clinically relevant in humans.Isojärvi et al. found an increased number of ovarian cysts in women on valproate monotherapy. A normalisation of such polycystic change was observed after discontinuation of valproate. However, there were corresponding improvements of insulin resistance and it is therefore uncertain whether valproate had a direct or an insulin mediated effect on the ovaries.

Antiepileptic drugs may decrease or increase biologically active serum sex hormone levels. Many of the older antiepileptic drugs—including carbamazepine, phenobarbital, and phenytoin—induce hepatic cytochrome P450-dependent steroid hormone breakdown and the production of sex hormone binding globulins (SHBG), thereby reducing biologically active sex hormone serum concentrations.

Decreases of free serum testosterone levels during carbamazepine treatment owing to the induction of sex hormone binding globulin have been documented. The free serum testosterone concentration rises when patients are switched from carbamazepine to oxcarbazepine, which causes less hepatic induction. A reduced rate of PCOS (a condition characterised by a high testosterone) in women treated for epilepsy with enzyme inducers compared with untreated women with epilepsy (13 vs 30%) has been shown. Other investigators have found that enzyme induction in carbamazepine treated women with epilepsy causes menstrual disturbance characterised by low oestradiol and a low oestradiol/SHBG ratio in 25% of cases.

Conversely, hepatic enzyme inhibitors can increase biologically active sex hormone levels. In a prospective study an increase in serum androgen concentrations was documented in women with newly diagnosed epilepsy who were started on valproate. In girls treated with valproate for a mean of two years, higher serum testosterone levels were found than in untreated controls. Testosterone levels in excess of 2 SD of the mean were found in 38% of prepubertal, 36% of pubertal, and 57% of postpubertal girls on valproate. It should be pointed out that the clinical relevance of a raised total and/or free testosterone level depends on the presence of symptoms of hyperandrogenism such as cycle disturbance, subfertility, male pattern hair loss, hirsutism, or acne. However, an increase in serum total or free testosterone may contribute to altered gonadotropin secretion and lead to manifestations of reproductive endocrine disorders, so that asymptomatic patients with an isolated elevation of total or free testosterone should be kept under endocrine review.

Several antiepileptic drugs may cause weight gain. This adverse effect has been described with valproate, carbamazepine, vigabatrin, and gabapentin. Weight gain and obesity have direct negative effects on many aspects of health and on life expectancy. Weight increase reduces insulin sensitivity and promotes PCOS development in patients who have no previous hormonal abnormality. Thus antiepileptic drug related weight increases could trigger the manifestation of a clinically relevant endocrine disorder. Weight related endocrine problems may be enhanced by the enzyme inhibiting effects of valproate, and masked by enzyme inducers like carbamazepine. Weight reduction after tapering off valproate has been shown to be associated with a normalisation of menstrual cycles and hormonal disturbances. There are no studies of the effects of weight reduction without change in drug treatment. It should be pointed out that valproate associated endocrine changes have also been observed in the absence of weight gain.

There has been intense debate over the existence of an overrepresentation of PCOS or isolated individual constituent components (polycystic ovaries or hyperandrogenism) in women receiving valproate for epilepsy. In a study of 238 women with epilepsy, 45% of 29 women on valproate monotherapy had menstrual irregularities (amenorrhoea, oligomenorrhoea, prolonged cycles, and irregular menstruation); 60% of these women also had polycystic ovaries and 30% who had raised serum testosterone concentrations. In a cross sectional study of 65 women with epilepsy, polycystic ovaries or hyperandrogenaemia were found in 14 of 22 patients taking valproate monotherapy (64%). This group comprised women with isolated polycystic ovaries, isolated hyperandrogenaemia, or both. The association of valproate with polycystic ovaries or
hyperandrogenaemia was supported by a multicentre study including women from Finland, Norway, and the Netherlands. Endocrine effects were more commonly seen in women beginning valproate before the age of 20. Discontinuation of valproate treatment led to a reversal of hyperinsulinemia, hyperandrogenism, dyslipidaemia, and polycystic ovaries in 12 women followed prospectively for one year. Isojärvi et al linked the finding of polycystic ovaries and hyperandrogenaemia with medication related weight gain, but they also observed an increased incidence of hormonal disturbances in lean women treated with valproate. They suggested that hyperinsulinemia and low serum levels of insulin-like factor binding protein 1 could lead to hyperandrogenism and polycystic ovaries. Muralidotta et al found confirmatory evidence for valproate related endocrine effects with polycystic ovaries in 40% of patients receiving valproate as part of their anticonvulsant polytherapy, versus 13% in patients not treated with valproate. They also found raised serum androgen levels and a reduced mid-luteal progesterone surge in valproate as compared with phenobarbitone or carbamazepine treated women as a marker of anovulation. However, two other cross sectional studies in 93 and 43 patients, respectively, failed to confirm an association between menstrual disturbance and a particular antiepileptic drug. 

MANAGEMENT OF WOMEN WITH EPILEPSY AND REPRODUCTIVE DISORDERS

The treatment of epilepsy aims for complete seizure control with as few side effects as possible. The choice of antiepileptic drug is driven by many considerations including proven efficacy for the particular seizure type, tolerability, the personal experience of the physician, and especially how comfortable the physician and the patient feel using a specific agent. In the treatment of women with epilepsy, several additional factors have to be considered. These include the safety of an antiepileptic drug during pregnancy, the compatibility of the antiepileptic drug with hormonal contraception, and the potential impact on reproductive function as outlined above. The panel does not consider any antiepileptic drug contraindicated for use in women. However, physicians should be aware of reproductive endocrine dysfunction that may occur in women with epilepsy during treatment. This requires regular monitoring of reproductive function at visits, including questioning about menstrual disorders, fertility, weight, hirsutism, and galactorrhoea. Particular attention should be paid to patients treated with valproate and those who are obese or who experience significant weight gain during treatment with antiepileptic drugs. Reproductive dysfunction warrants diagnosis. This often requires the aid of appropriate investigations that may include hormonal tests, pelvic ultrasound, and pituitary imaging. The diagnosis of a reproductive endocrine disorder should then be considered in terms of aetiology and potential contributory factors, including epilepsy and antiepileptic drugs. Single abnormal laboratory tests (for example, increased serum testosterone) or imaging findings (such as polycystic ovarian structure) may not constitute a clinically relevant endocrine disorder. Such findings, however, should alert the physician to a greater potential for the development of a clinically relevant disorder and the need for closer clinical and possibly investigational monitoring.

If a reproductive endocrine disorder is found, antiepileptic drug treatment should be reviewed to ensure that it is correct for the particular seizure type and that it is not contributing to the endocrine problem. The possible benefits of a change of antiepileptic drug treatment must be balanced against seizure control and cumulative side effects of alternative agents. Many of the newer antiepileptic drugs have not been studied with regard to (longer term) endocrine reproductive side effects, and little is known about their safety in pregnancy. If a patient is seizure-free on an antiepileptic drug that could be the cause of adverse reproductive endocrine effects, a monotherapy switch is fraught with the risk of seizure relapse, and lower dose combination treatment with the risk of additional side effects.

Although our understanding of the effects of seizures and antiepileptic drugs on reproductive endocrine function remains incomplete, we are able to identify women with epilepsy who have reproductive dysfunction and may benefit from endocrine investigation and therapeutic intervention. Every clinic involved in the management of epilepsy should be aware of the high prevalence and medical significance of reproductive disorders in women with epilepsy.

CONCLUSIONS

- Reproductive dysfunction and reproductive endocrine disorders are unusually common among women with epilepsy.
- Reproductive disorders probably contribute to the decreased fertility in women with epilepsy.
- Reproductive function should be screened regularly, looking for menstrual disorder, infertility, obesity or weight gain, hirsutism, and galactorrhoea.
- Reproductive dysfunction may require further assessment with endocrine testing, pelvic ultrasound, and pituitary imaging.
- The diagnosis of a reproductive endocrine disorder should be considered in terms of aetiology and potential contributory factors, including epilepsy and antiepileptic drugs (in particular valproate).
- The possible benefits of a change of antiepileptic drug treatment must be balanced against efficacy in terms of seizure control and the side effects of alternative agents.
- The comprehensive management of women with epilepsy includes counselling about reproductive issues that relate to epilepsy and antiepileptic drug use, as well as monitoring of reproductive function.

Authors’ affiliations

J Bauer, C E Elger, Department of Epileptology, University of Bonn, Bonn, Germany
J I T Isojärvi, Department of Neurology, University of Oulu, Finland
J G Herzog, Harvard Neuroendocrine Unit, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
M Reuber, Department of Neurology, Leeds Teaching Hospitals, Leeds, UK
D Polson, Department of Gynaecology, Hope Hospital, Manchester, UK
E Toubaüll, Department of Neurology, Rikshospitalet, University of Oslo, Oslo, Norway
P Genton, Centre Saint Paul, Marseille, France
H van der Ven, B Roessing, Department of Gynaecological Endocrinology, University of Bonn, Bonn, Germany
G J Luef, Department of Neurology, University of Innsbruck, Innsbruck, Austria
C A Galimberti, Epilepsy Centre, Neurological Institute “C Mondino” Foundation, Pavia, Italy
J van Parys, Epilepsiecentrum Kempenhaeghe, Heeze, The Netherlands
D Flügel, Department of Neurology, University of Regensburg, Regensburg, Germany
A Bergmann, Neurologist, Neuburg/Donau, Germany

REFERENCES

Reproductive dysfunction in women with epilepsy


29 Isojärvi JI. Serum steroid hormones and pituitary function in female epileptic patients during carbamazepine therapy. Epilepsia 1990;31:438–45.


